Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Berzosertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR known ✓ | Q13535 | 20/20 | 1.00 |
| ▸ | ATM | Q13315 | 10/20 | 1.00 |
| ▸ | PRKDC | P78527 | 5/20 | 1.00 |
| ▸ | GSK3B | P49841 | 3/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | KIT | P10721 | 1/20 | 1.00 |
| ▸ | SERPINA2 | P20848 | 1/20 | 1.00 |
| ▸ | PIK3R1 | P27986 | 1/20 | 1.00 |
| ▸ | FLT4 | P35916 | 1/20 | 1.00 |
| ▸ | FLT3 | P36888 | 1/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 1/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | SYK | P43405 | 1/20 | 1.00 |
| ▸ | GSK3A | P49840 | 1/20 | 1.00 |
| ▸ | MAP3K9 | P80192 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | MERTK | Q12866 | 1/20 | 1.00 |
| ▸ | DYRK2 | Q92630 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Berzosertib SCHEMBL3061890 | 1.00 | ATR (1.00) | ATRATMPRKDCGSK3BJAK2 | |
| Berzosertib SCHEMBL15120027 | 0.95 | ATR (0.90) | ATRATMPRKDCGSK3BJAK2 | |
| Berzosertib SCHEMBL15120037 | 0.95 | ATR (0.90) | ATRATMPRKDCGSK3BJAK2 | |
| Berzosertib SCHEMBL15120034 | 0.94 | ATR (0.88) | ATRATMPRKDCGSK3BJAK2 | |
| Berzosertib SCHEMBL15120028 | 0.94 | ATR (0.88) | ATRATMPRKDCGSK3BJAK2 | |
| Berzosertib SCHEMBL15120036 | 0.94 | ATR (0.88) | ATRATMPRKDCGSK3BJAK2 | |
| Berzosertib SCHEMBL15120033 | 0.94 | ATR (0.88) | ATRATMPRKDCGSK3BJAK2 | |
| Berzosertib SCHEMBL15120029 | 0.94 | ATR (0.88) | ATRATMPRKDCGSK3BJAK2 | |
| Berzosertib SCHEMBL14829895 | 0.94 | ATR (0.88) | ATRATMPRKDCGSK3BJAK2 | |
| Berzosertib SCHEMBL15120024 | 0.93 | ATR (0.86) | ATRATMPRKDCGSK3BJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3856251-B1 | COMBINATION OF A PD-1 ANTAGONIST, AN ATR INHIBITOR AND A PLATINATING AGENT FOR THE TREATMENT OF CANCER | MERCK PATENT GMBH (DE) | 2024-10-09 | — | — | EP | claimed |
| US-20250352539-A1 | COMBINATION THERAPY FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2025-11-20 | — | — | US | disclosed |
| WO-2025080711-A1 | DUAL PAYLOAD ANTIBODY DRUG CONJUGATES | SUTRO BIOPHARMA, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| CN-119317434-A | Combination therapy for the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2025-01-14 | — | — | CN | disclosed |
| CN-118878534-A | Imidazolone quinoline compounds and therapeutic uses thereof | 默克专利股份公司 | 2024-11-01 | — | — | CN | disclosed |
| CN-113614083-B | Imidazolone quinoline compounds and therapeutic uses thereof | 默克专利股份公司 | 2024-08-27 | — | — | CN | disclosed |
| WO-2023166077-A1 | COMBINATION OF A CTPS1 INHIBITOR AND A ATR INHIBITOR IN CANCER THERAPY | STEP PHARMA S.A.S. (FR) | 2023-09-07 | — | — | WO | disclosed |
| CN-116507335-A | ATR inhibitors for the treatment of viral infections | 默克专利股份公司 | 2023-07-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250352539-A1 | COMBINATION THERAPY FOR TREATING CANCER | PARP1, ATR, PARP11 | ATR 2/4885ATM 23/4885PRKDC 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.